Mirtazapine is an antidepressant. It belongs to a class called noradrenergic and specific serotonergic antidepressants, often shortened to NaSSA, and it has been approved for the treatment of major depressive disorder since the mid-1990s. The confusion with antipsychotics is understandable, though, because mirtazapine sometimes shows up in treatment plans for people with schizophrenia, and its side-effect profile overlaps with certain antipsychotic medications in ways that blur the line for patients reading their own prescription information.
How Mirtazapine Actually Works
Mirtazapine’s mechanism is unlike both the common SSRIs (like fluoxetine or sertraline) and the antipsychotics (like olanzapine or risperidone). It works by blocking specific receptors that normally act as brakes on the release of norepinephrine and serotonin. By knocking out those brakes, it allows both of those neurotransmitters to flow more freely. It also blocks certain serotonin receptor subtypes, which helps shape which serotonin pathways get activated and which don’t.1PubMed Central. A review of the pharmacological and clinical profile of mirtazapine
On top of all that, mirtazapine has a strong affinity for histamine receptors. That histamine-blocking action is largely responsible for two of its most recognizable effects: sedation and appetite stimulation.2PubMed Central. Mirtazapine is a functional antagonist at cardiac human H1-histamine receptors This is the same receptor system that makes over-the-counter antihistamines like diphenhydramine cause drowsiness, except mirtazapine binds to it with considerably more strength. It also binds weakly to muscarinic receptors, which means it tends to cause fewer of the dry mouth and constipation issues that older tricyclic antidepressants are known for.
Why People Confuse It With Antipsychotics
The mix-up usually traces back to a few things happening at once. Mirtazapine is frequently prescribed alongside antipsychotic medications to people with schizophrenia. It causes weight gain and sedation, which are side effects people associate with antipsychotics. And it has “tetracyclic” in its chemical description, which sounds vaguely clinical and unfamiliar enough to leave people guessing about its category.
The critical distinction is dopamine. Antipsychotic drugs work primarily by blocking dopamine D2 receptors in the brain, particularly in the striatal regions involved in psychotic symptoms. Mirtazapine does not do this. Research has confirmed that mirtazapine has no meaningful affinity for dopamine receptors, and there is no evidence that it increases dopamine release in the striatal areas where antipsychotics exert their effects.3PLOS ONE. Striatal Dopamine D2/3 Receptor Availability in Treatment Resistant Depression It does appear to increase dopamine in the prefrontal cortex through an indirect route involving serotonin and norepinephrine receptors, but that is a very different thing from the broad dopamine blockade that defines antipsychotic action.
Without dopamine receptor blockade, mirtazapine cannot treat psychosis on its own. No clinician prescribes it as a standalone treatment for schizophrenia or bipolar mania. When it appears in a schizophrenia patient’s medication regimen, it is always playing a supporting role, not the lead.
Its Role in Schizophrenia Treatment
So why does mirtazapine show up in prescriptions for people with schizophrenia at all? The answer lies in what antipsychotics are not great at: negative symptoms. Schizophrenia involves positive symptoms (hallucinations, delusions) and negative symptoms (emotional flatness, social withdrawal, loss of motivation). Antipsychotics handle the positive symptoms reasonably well but often leave the negative symptoms largely untouched. Mirtazapine, when added to an antipsychotic, has shown some ability to help with those harder-to-treat symptoms.
A meta-analysis of five studies found a statistically significant improvement in negative symptoms when mirtazapine was added to antipsychotic treatment, though the studies varied quite a bit in their individual results.4PubMed. Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia One randomized controlled trial found that adding mirtazapine to risperidone improved negative symptoms and also gave a modest boost to cognitive function in areas like vocabulary and immediate memory.5Progress in Neuro-Psychopharmacology and Biological Psychiatry. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone
A Cochrane systematic review, however, struck a more cautious note. It concluded that the available evidence was primarily of very low quality and that mirtazapine as an add-on was not clearly associated with an effect on negative symptoms, though there was some indication of a positive effect on overall mental state.6PubMed Central. Mirtazapine adjunct for people with schizophrenia The evidence here is genuinely thin, which is worth keeping in mind when you see mirtazapine discussed in the context of psychotic illness.
Treating a Side Effect of Antipsychotics
Another reason mirtazapine appears in the same conversation as antipsychotics is that it’s one of the more effective treatments for akathisia, a deeply unpleasant restlessness that antipsychotic drugs can cause. People with akathisia feel an almost unbearable urge to move; they pace, shift their weight, or fidget constantly. It’s one of the main reasons people stop taking their antipsychotic medication.
A large systematic review and network meta-analysis compared ten medications used to treat antipsychotic-induced akathisia. Mirtazapine at just 15 mg per day ranked as the most effective option, outperforming propranolol, biperiden, vitamin B6, and several others.7JAMA Network Open. Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia In one randomized trial, about half of patients taking mirtazapine met the response threshold within five days, compared to fewer than one in ten on placebo.8PubMed. Role of mirtazapine in the treatment of antipsychotic-induced akathisia This is clinically useful because it means a prescriber can use mirtazapine to manage both akathisia and comorbid depressive or negative symptoms at once, which simplifies the medication regimen.9PubMed Central. Reassessing mirtazapine and akathisia
This dual utility probably deepens the confusion. If a person with schizophrenia is taking an antipsychotic and their doctor adds mirtazapine to treat the akathisia that antipsychotic caused, it’s easy to assume everything in the regimen is an antipsychotic. But mirtazapine is still functioning as an antidepressant with useful receptor-blocking properties, not as an antipsychotic in its own right.
How Mirtazapine Compares to Other Antidepressants
Within the antidepressant world, mirtazapine holds its own. A Cochrane review comparing it to other antidepressants found that mirtazapine was more effective than SSRIs at two weeks and at the end of acute treatment. It also outperformed venlafaxine, a serotonin-norepinephrine reuptake inhibitor, on both of those time points.10PubMed Central. Mirtazapine versus other antidepressive agents for depression The faster onset of action is one of mirtazapine’s distinguishing features. Most SSRIs take three to four weeks before a patient notices meaningful improvement; mirtazapine often starts showing effects within the first two weeks.
A broader review described mirtazapine as being as effective as other antidepressants overall, with the edge in speed being its main clinical advantage.11PubMed. Mirtazapine: a review of its use in major depression and other psychiatric disorders More recent evidence also suggests it performs well when anxiety is part of the picture. A systematic review found mirtazapine was more effective than SSRIs for anxiety symptoms that accompany major depression, and it showed promise in generalized anxiety disorder and as an augmentation strategy in PTSD.12PubMed. Clinical Potential of Mirtazapine in Anxiety and Trauma-Related Disorders
Weight Gain and Metabolic Effects
Here is where mirtazapine’s reputation gets tangled up with antipsychotics in another way. Among antidepressants, mirtazapine carries one of the highest risks of weight gain, putting it in the same conversation as the antipsychotics olanzapine and clozapine, which are infamous for the same problem.13PubMed. Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants The mechanism is at least partly related to its histamine receptor blockade and the appetite increase that comes with it.
There is an important distinction, though. The metabolic fallout from mirtazapine’s weight gain appears to be less severe than what happens with the worst antipsychotic offenders. Antidepressants associated with weight gain tend to produce fewer unfavorable effects on glucose and lipid metabolism than antipsychotics like clozapine and olanzapine. So while the number on the scale may move in a similar direction, the downstream metabolic consequences may differ. This does not mean weight gain on mirtazapine is harmless. It remains the side effect that most often leads people to discontinue the medication or ask for an alternative.
The Low-Dose Sedation Paradox
One of the more counterintuitive things about mirtazapine is that it tends to be more sedating at lower doses than at higher ones. At 15 mg, many people find it quite sedating. At 30 or 45 mg, the sedation often lessens. This is because at lower doses, the histamine-blocking effect dominates. As the dose increases, the norepinephrine-boosting effects kick in more strongly and partially counteract the drowsiness.
This quirk has practical consequences. In Sweden, researchers have flagged a trend of adolescents receiving mirtazapine at a mean dose well below the therapeutic range for depression, apparently as a sedative alternative to benzodiazepines rather than as an antidepressant.14medRxiv. A Public Health Concern: The Rising Off-Label Use of Low-Dose Mirtazapine in Swedish Adolescents Swedish adolescents were receiving mirtazapine prescriptions at more than double the rate of their Danish peers. Whether using mirtazapine primarily for its sedation is a sound clinical strategy is debated, but the practice highlights how the drug’s behavior shifts dramatically depending on the dose.
An exploratory analysis looking at whether higher mirtazapine doses produced more adrenergic side effects (things like agitation, insomnia, or anxiety) found no clear association between dose and the likelihood of experiencing those effects.15PubMed Central. Relationship between mirtazapine dose and incidence of adrenergic side effects In other words, the fear that going to a higher dose will make you jittery or anxious does not appear to be borne out by the data.
Sexual Side Effects Are Notably Low
One of the genuine advantages mirtazapine holds over SSRIs is in the sexual side-effect department. SSRIs are notorious for causing decreased libido, difficulty reaching orgasm, and other sexual problems. In a naturalistic study comparing newer antidepressants, mirtazapine had a sexual dysfunction rate of about 18%, compared to roughly 46-60% for common SSRIs like fluoxetine, paroxetine, and citalopram.16PubMed Central. Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting This makes mirtazapine a go-to alternative for people who have found SSRI-related sexual side effects intolerable.
This difference makes pharmacological sense. SSRIs cause sexual dysfunction largely by flooding serotonin receptors indiscriminately, including the 5-HT2 and 5-HT3 subtypes that are involved in inhibiting sexual function. Mirtazapine blocks those exact subtypes. So instead of activating the serotonin pathways that suppress sexual function, it specifically shuts them down while boosting the serotonin pathways (via 5-HT1A) that are more associated with mood improvement.
Appetite Stimulation Beyond Depression
Mirtazapine’s appetite-boosting effect is a side effect in people trying to maintain their weight, but it becomes a therapeutic tool for patients who are dangerously underweight or struggling to eat. A randomized clinical trial in patients with non-small cell lung cancer and anorexia found that the mirtazapine group significantly increased their daily energy consumption by roughly 380 kilocalories after four weeks, with corresponding increases in protein, carbohydrate, and fat intake.17JAMA Oncology. Mirtazapine as Appetite Stimulant in Patients With Non–Small Cell Lung Cancer and Anorexia
The picture is more mixed in older adults. A retrospective study of hospitalized older adults found that mirtazapine’s appetite-stimulating effect varied by underlying condition. Patients with cancer-related appetite loss showed meaningful improvement, but those with major neurocognitive disorders (such as dementia) were less likely to benefit.18The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice. Mirtazapine for Poor Appetite in Hospitalized Older Adults With Major Neurocognitive Disorder or Oncologic Illness This suggests the appetite effect has limits and doesn’t work equally well in all clinical scenarios.
Combination Strategies and “California Rocket Fuel”
In treatment-resistant depression, where a first-line antidepressant has not worked, mirtazapine is often combined with other antidepressants rather than replaced by an antipsychotic augmenter. The most well-known combination is mirtazapine plus venlafaxine, sometimes called “California Rocket Fuel” in psychiatric slang. The idea is that the two drugs attack depression from complementary angles: venlafaxine blocks the reuptake of serotonin and norepinephrine, while mirtazapine boosts both from a different direction and blocks the serotonin receptor subtypes that cause many of venlafaxine’s side effects.
Preclinical research has shown that combining sub-effective doses of mirtazapine and venlafaxine still produced an antidepressant effect, and the combination did not inhibit sexual behavior in the animal model tested.19PubMed Central. The combination of mirtazapine plus venlafaxine reduces immobility in the forced swim test and does not inhibit female sexual behavior Clinical experience supports the general idea that this pairing can rescue some treatment-resistant cases, though the controlled trial evidence for the specific combination in humans is not as robust as prescribing patterns might suggest.
How Multiple Liver Enzymes Keep Mirtazapine Predictable
One practical consideration that separates mirtazapine from many other psychotropic drugs is its metabolism. Mirtazapine is broken down in the liver by at least three different enzyme systems. Because several enzymes share the work, a problem with any single enzyme, whether caused by genetics, another medication, or even diet, is less likely to send mirtazapine levels dangerously high or low.20Drug Metabolism and Disposition. Metabolism of the Antidepressant Mirtazapine in Vitro This built-in redundancy makes drug interactions with mirtazapine somewhat less of a minefield compared to drugs that depend heavily on a single enzyme pathway.
That said, “less of a minefield” is not the same as “no concerns.” Taking mirtazapine alongside strong inhibitors of multiple enzyme pathways simultaneously could still raise blood levels. Prescribers generally check for interactions, but patients taking complex medication regimens should flag any new additions with their pharmacist or doctor.
Mirtazapine and Mianserin
People who dig into mirtazapine’s background eventually encounter mianserin, the older tetracyclic antidepressant from which mirtazapine was derived. Mirtazapine is essentially mianserin with a single nitrogen atom swapped in for a carbon atom in one of its rings. That small change has surprisingly large consequences. It alters the molecule’s polarity, its electrical charge distribution, and its tendency to interact with different receptors.21PubMed. A comparison of the physicochemical and biological properties of mirtazapine and mianserin Mirtazapine ended up with lower affinity for the receptor that causes orthostatic hypotension (a drop in blood pressure when standing up) and essentially no norepinephrine reuptake activity, both of which made it a cleaner drug with fewer cardiovascular side effects than its predecessor.
Both drugs share serotonin receptor-blocking properties, and recent structural research has found that mirtazapine, mianserin, and a related compound called setiptiline unexpectedly activate certain serotonin receptors linked to migraine pathways. That finding, while still early, suggests these tetracyclic antidepressants may have antimigraine properties that were previously unrecognized.22PubMed Central. Structural insights into the unexpected agonism of tetracyclic antidepressants at serotonin receptors 5-HT1eR and 5-HT1FR Whether this translates into clinical migraine prevention is an open question, but it illustrates how mirtazapine’s receptor profile keeps revealing new facets decades after its approval.